To crack the code of FSHD, patients are absolutely essential
All of the breakthroughs—the discovery of the genetic causes, understanding why some patients vary so greatly in the severity of their symptoms, teasing out the biochemical pathways that could point to future treatments—were made because patients stepped up to the plate.
Too often, we hear patients say they’ll volunteer when there’s a treatment. But we will never get to a treatment unless patients participate in fundamental research now. FSHD is uniquely human, so no laboratory mouse can ever fully model the disease. The genetic “package” that causes FSHD is found only in people. We owe an enormous debt to the patients who give DNA samples. Who submit to long interviews and exhausting physical tests. Allow a surgeon to cut out a small muscle sample. Who fight claustrophobia to lie in the narrow bore of an MRI machine.
Equally important are patients’ family members, both affected and unaffected, who provide the best experimental controls because of their shared genetic and environmental backgrounds. A parent or sibling who has very mild symptoms may hold the key to understanding the factors that protect against the full-blown development of FSHD symptoms in a more severely affected family member.
We are more hopeful today than ever before that a treatment is within sight. We cannot guarantee when that treatment will arrive, but here’s one thing we guarantee: If you volunteer for research, your participation will without question help move us a step closer to that day.
Scientific Overview of FSHD
Read the latest on wikipedia
Glossary of Scientific Terms
Bay Area Family Day Video and Slides
Here are the slides and videos from the Bay Area Family Day conference, held at the Li Ka Shing Center, Stanford Medical School, on Sunday, April 28, 2019. Click on… Read More »
European centers to collaborate on FSHD ReSOLVE study
Three European centers have agreed to collaborate with the FSHD Clinical Trial Research Network on its NIH UO1 grant-funded projects, notably ReSOLVE. In doing so, they join eight US members… Read More »
Finding FSHD: the story of DUX4 in a zebrafish
by Amanda Hill, Highlands Ranch, Colorado When studying human disease and working to develop treatments, researchers typically perform experiments on animal models that represent the disease in a controlled laboratory… Read More »
Fulcrum Acquires Global Rights to a Potential Disease-Modifying Therapy for FSHD
From Fulcrum Therapeutics press release. Fulcrum plans to launch a Phase 2b clinical trial in FSHD in mid-2019 CAMBRIDGE, Mass., April 23, 2019 – Fulcrum Therapeutics, a biotechnology company focused… Read More »